Other Events ·
Immutep receives €1.36 million French R&D tax incentive for 2025 activities
PRRUFIMMUTEP Ltd
Immutep Limited has received a cash payment of €1.36 million (approximately A$2.16 million) from the French Government under its Crédit d’Impôt Recherche (CIR) research tax incentive program. The refund covers eligible R&D expenditure for calendar year 2025 conducted by Immutep’s French subsidiary, Immutep S.A.S. This funding follows a recent A$0.86 million rebate from the Australian Government and supports current development of product candidates eftilagimod alfa and IMP761. The non-dilutive capital contributes to an expected cash runway extending into the first half of 2028. Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases.